# About Peptide Med Group — An Independent Research Peptide Desk

> About Peptide Med Group: an independent literature digest ranking ipamorelin, NAD+, thymosin alpha-1, and tirzepatide by clinical-trial depth. Not a vendor, not a clinic, not medical advice.

An independent record of what the trials found. Not a clinic. Not a vendor.

## What Peptide Med Group is

Peptide Med Group tracks four research peptides — ipamorelin, NAD+, thymosin alpha-1, and tirzepatide — organized around one question: how much clinical-trial evidence actually exists for each, and what did it find. Tirzepatide leads this desk because its trial record is the deepest of the four: multiple completed Phase 3 programs and FDA approval. The other three sit at different points on the same scale, from thymosin alpha-1's real but null Phase 3 sepsis trial, to NAD+'s solid smaller trials on biomarkers, to ipamorelin's single negative human study.

The organizing discipline is simple: state what a specific trial tested, in whom, and what it found. Don't round a Phase 2 signal up to a clinical fact. Don't let a compound's marketing outrun its evidence. Where a trial failed its primary endpoint, this desk says so — that's data too.

## How it is compiled

Every factual claim on this site ties to a numbered citation, collected on the [references page](/references) — peer-reviewed journal articles, clinical-trial publications, and clinical-reference chapters, each with a DOI or PubMed link. Where a claim comes from a review rather than a primary trial, the text says so.

Findings are reported at the strength they were actually studied at. A rat study is reported as a rat study. A Phase 2 trial that missed its endpoint is reported as a trial that missed its endpoint, not softened into a maybe. Where a compound's real-world community reports exist, they're labeled as anecdotal and kept separate from the cited clinical record — the two are never blended into one claim.

The four compound pages cross-reference each other and a shared [comparison page](/compare), so a reader can follow one theme — trial depth, mechanism, safety signal — across all four.

## What it is not

Peptide Med Group is not a pharmacy, a clinic, or a vendor. It doesn't sell, source, or broker any compound, and it has no referral relationship with any manufacturer, telehealth provider, or research-chemical supplier. It doesn't diagnose, prescribe, or recommend a dose for any person.

Tirzepatide is a prescription medicine, available only through a licensed provider. Thymosin alpha-1 is approved abroad, not in the US. NAD+ is sold as a supplement and, in injectable form, as a compounded product. Ipamorelin has no approval anywhere. Readers seeking clinical guidance should consult a licensed provider in their own jurisdiction. Editorial correspondence — citation corrections, new trial results — goes through the [contact page](/contact).

---

This is a citation ledger, not a clinic — we report what the trials found and stop there.